Tag Archives: Retirement Investments

Cover Preview: Barron’s Magazine – Dec 5, 2022

Magazine - Latest Issue - Barron's

@barronsonline December 5, 2022 issue:

A Big Chill Is Here for the Housing Market. Next Year Could Bring More Trouble.

Affordability is still an issue, mortgage rates will remain high, and homes are sitting on the market longer. It all adds up to a stalled 2023 for real estate.

Strong Job Numbers Throw Cold Water on Hopes for End to Rate Rises

The Fed’s Inflation Fight Must Cause More Pain—to the Job Market

Another Bad Sign for Tech Stocks—Cloud Spending Is Fading

Wall Street Isn’t Fond of T. Rowe Price, but Maybe You Should Be

Cover Preview: Barron’s Magazine – Sept 26, 2022

Image

Tumbling Markets Imperil Tech, the Dollar, and Private Equity

Randall W. Forsyth

TECHNOLOGY TRADER

A Small-Cap Way to Play Streaming’s Next Big Opportunity

Eric J. Savitz

THE TRADER

September Was Bad for Investors. October Could Be Worse.

Nicholas Jasinski

INCOME INVESTING

5 Dividend Picks to Beat Inflation and Rising Rates

Lawrence C. Strauss

STRIKING PRICE

How a ‘Put-Spread Collar’ Protects Your Portfolio

Steven M. Sears

STREETWISE

Stocks Are Sinking and Rates Are Rising. It’s Painful, But We’re Heading for Normal.

Cover Preview: Barron’s Magazine – August 29, 2022

Image

How Water Scarcity Threatens the Global Economy

The scarcity of fresh water is rapidly emerging as a global economic threat that could disrupt businesses, crimp profits, and jeopardize growth. Companies, regulators, and investors are starting to react.

The Stock Market Finally Heard Powell’s Message. It Won’t Be Pretty.

Ben Levisohn

Juniper Networks Had Lousy Earnings. It’s AI Strategy Could Help the Stock Break Out.

Ben Levisohn

California Sets the Pace on Zero Emissions. Car Makers, Old and New, Are Cheering.

Al Root

Why Apple Might Push Deeper Into Sports Streaming

Eric J. Savitz

Fed Chief Talks Tough on Inflation. Stocks Listen and Fall Sharply

Cover Preview: Barron’s Magazine – May 16, 2022

Barron’s Magazine, May 16, 2022 – How Workers Gained Leverage, and Why They Won’t Lose It Soon

Employees in many industries have seized on the pandemic’s upheaval to score higher pay, better benefits, flexible schedules, and more. While some gains will fade, a number of economic and demographic forces suggest workers have the edge.

Investment Portfolios: Health Care Stocks For Boomers To Invest In

“To cash in on these long-term trends, we scoured the sector and found eight good opportunities. The stocks we like fall into three broad health care areas: drugmakers, health care service providers, and medical device and equipment manufacturers. Their share prices may continue to bounce around, especially as we near the 2020 elections. Smart investors will buy more when shares dip. “If you have flexibility and you can pick your spots, you can make money,” says Matt Benkendorf, chief investment officer at money management firm Vontobel Quality Growth.”

  • Merck (symbol MRK, price $83) is an elder statesman in the pharma world that should continue to thrive in the new order. Keytruda, Merck’s immunotherapy drug that basically gets the immune system to kill cancer cells, is “rapidly becoming one of the largest products we’ve ever seen,” says JPMorgan Chase analyst Christopher Thomas Schott.
  • Neurocrine Biosciences (NBIX, $84) is expected to be profitable in 2020. It has two drugs on the market and a strong pipeline of therapies in all stages of development. One of its commercial drugs, Ingrezza, is a “best in class” therapy for tardive dyskinesia, a condition that causes jerky, involuntary face and body movements, says Credit Suisse’s Seigerman. He thinks it could fetch annual sales of $2 billion by the early 2020s.
  • CVS Health (CVS, $54) aims to give UnitedHealth a run for its money. It’s best known for its drugstores—70% of people in the U.S. live within three miles of a CVS pharmacy—but it operates more than 1,000 walk-in clinics, too. With its acquisition of Aetna in late 2018, CVS is now also an insurer.
  • After spinning off its drug division in 2013, Abbott Laboratories (ABT, $82) now focuses on a diverse roster of products that includes nutritional drinks, diagnostics, generic drugs and medical devices. But a trio of new products put it in the sweet spot of the health care sector’s innovation surge, says William Blair’s Golan. 

Read more in Kiplinger’s: https://www.kiplinger.com/article/investing/T052-C000-S002-9-health-care-stocks-for-your-portfolio.html

Health Care Stocks for Boomers to Invest in